Professor Claire Harrison graduated became a consultant at the Guy’s and St Thomas Hospital in 2001, where she is now a deputy chief medical officer.  

The focus of her clinical work is myeloproliferative neoplasms (MPN), key areas of interest are clinical trials and associated translational research. Her work has led to the approval of new therapies such a ruxolitinib, fedratinib, momelotinib and pacritinib. In the past 10 years she has published widely (>300 academic articles).  

In addition she has a strong interest in patient advocacy and founded the UK MPN group www.mpnvoice.org.uk. 

Prof. Claire Harrison has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Novartis, Keros, Takeda, Syntara, GSK, Galecto, DISC, Silence, BMS, Pharma&, Incyte, Johnson & Johnson, Karyopharm, Kartos, Menarini Stemline, Damora, IiOMEDICO, Calytrix, Alethiomics, MSD, AOP, Deciphera, Birmingham University, Blood Cancer UK, MPN Voice